Marc is the Portfolio Manager for Aquilo Capital Management. He has over 20 years experience in biotechnology research and investing. Previously, Marc was on the three person portfolio management team at the Biotechnology Value Fund (1995-2009). Marc has served on the Board of Directors of several private biotechnology companies. Marc is a graduate of the University of California, Santa Barbara with a B.A. in Biological Sciences and has a J.D. from Santa Clara University.

Jeremy is the Chief Operating Officer at Aquilo Capital Management. He joined Aquilo in April 2022. Prior to joining Aquilo, Jeremy was a Managing Director with SCP Investment, LP, a boutique alternative asset management firm. While at SCP from 2019 through 2022, Jeremy served as the head of both manager research and business development. From 2002 through 2019, Jeremy worked with GCM Grosvenor in Chicago, one of the oldest and largest alternative asset management organizations globally. While at Grosvenor, Jeremy was a Managing Director and the head of global equities and event-driven strategies within the hedge fund strategies business. Jeremy holds a BBA in Finance and International Business from The George Washington University and is a CFA charterholder.

Adam is the Director of Research at Aquilo Capital Management. He joined Aquilo in January 2010. Prior to joining Aquilo, he served as an Associate at the Biotechology Value Fund, assisting in sourcing and evaluating private and public biotechnology companies. He is a Class 14 Kauffman Fellow and was formerly on the Board of Directors of Airmid and Viriome Inc. Adam was a postdoctoral fellow in Neurobiology at Stanford University’s School of Medicine and has a Ph. D. from Yale University.

Patrick joined Aquilo Capital in 2014. From 2005-2014 he worked as a research scientist in various drug development capacities for several public and private biotech firms, including Sutro Biopharma, Exelixis and Xoma. This experience includes research and development for preclinical and clinical stage products in oncology and inflammatory diseases. Patrick received his B.S. in Chemical Engineering at UCLA and his MBA from UC Berkeley’s Haas School of Business.

Katerina earned her PhD in Biomedical Sciences from UCSF & MIT in the laboratory of Jonathan Weissman. During her PhD, she studied mechanisms of protein folding using functional genomics methods.

She has become an expert in ribosome profiling, CRISPR engineering, genome wide genetic interaction screening, single cell technologies and has adapted these tools to answer fundamental biology about human disease. She is also developing tools to enable proteomics at the single cell level. Prior to her PhD, Katerina spent two years working in the laboratory of Benjamin Ebert at the Broad Institute developing in vivo mouse models of leukemia to identify novel therapeutic targets. Katerina holds a BS in Biology from Smith College where she graduated summa cum laude.

Christian joined Aquilo Capital in 2022 as a Research Analyst. He earned his M.Sc. in Physiology and Pharmacology at the University of Western Ontario (UWO), where he studied structure-based drug design. He also served as a clinical researcher for the McMaster University Department of Anesthesia, helping to launch and coordinate clinical trials investigating novel regional anesthetic techniques. Christian received his B.Sc. from UWO in 2019, where he double majored in Pharmacology and Biology.